This report studies the global Artificial Pancreas Devices Systems market status and forecast, categorizes the global Artificial Pancreas Devices Systems market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
Click to view the full report TOC, figure and tables：
The Artificial Pancreas Device System is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.
Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a “closed-loop” system, an “automated insulin delivery” system, or an “autonomous system for glycemic control.”
An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
The classification of artificial pancreas devices systems includes threshold suspended device systems and hybrid closed-loop APDS, and the proportion of artificial pancreas devices systems in 2017 is about 60%, and the proportion is in decreasing trend from 2013 to 2017.
Artificial pancreas devices systems are widely used in hospital and clinic. The most proportion of artificial pancreas devices systems is in hospital, and the proportion in 2017 is about 59%.
North America is the largest consumption place, with a consumption market share nearly 54% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 35%.
The global Artificial Pancreas Devices Systems market is valued at 56 million US$ in 2017 and will reach 140 million US$ by the end of 2025, growing at a CAGR of 12.1% during 2018-2025.
The major manufacturers covered in this report
Tandem Diabetes Care
Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
We can also provide the customized separate regional or country-level reports, for the following regions:
Rest of Asia-Pacific
Rest of Europe
Central & South America
Rest of South America
Middle East & Africa
Rest of Middle East & Africa
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Threshold Suspended Device Systems
Hybrid Closed-loop APDS
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Request Sample Copy of the Report @
About US:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.
QY Research, INC.
17890 Castleton, Suite 218,
City of industry, CA – 91748
USA: +1 6262 952 442
China: +86 1082 945 717
Japan: +81 9038 009 273
India: +91 9766 478 224
Emails – firstname.lastname@example.org
Web – www.qyresearch.com
Expert News: https://www.qyresearch.com/expert/list